Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Clin Cancer Res. 2012 Oct 22;19(1):279–290. doi: 10.1158/1078-0432.CCR-12-1558

Table 1.

Axl inhibition reverses EGFR resistance in mesenchymal cell lines.

A549 Calu-1 H157 H1299 H460 H2882
Erlotinib IC50 (μM) 13.54 >100 48.50 >100 >100 >100
SG-Axl-I IC50 (μM) 0.92 2.44 0.74 1.74 2.01 4.29
CI @IC50 0.46 >1.00* 0.67 0.72 0.57 >1.00*
Combination: Erlotinib + SG-Axl-I IC50 (μM) 1.07 + 0.35 13.86 + 4.47 1.46 + 0.47 3.76 + 1.21 3.53 + 1.14 16.44 + 5.30
*

for Calu-1 and H2882, the combination was antagonistic at IC50 but synergistic at higher concentration of SG-Axl-i.